替格瑞洛与氯吡格雷在经皮冠状动脉介入治疗冠心病中的临床效果

摘要

Objective:To analyze the clinical effect of ticagrelor and clopidogrel in the coronary heart disease patients with percutaneous coronary intervention(PCI).Methods:90 cases of coronary heart disease patients with PCI treatment were selected. They were randomly divided into the study group and the control group with 45 cases in each.The control group was given clopidogrel treatment.The study group was given ticagrelor treatment.The changes of coagulation function index changes and platelet aggregation rate before and after treatment were compared between groups.Results:After treatment,the activated partial thromboplastin time,prothrombin time of the study group were significantly shorter than those of the control group,and the thrombin time was significantly longer than that of the control group,the fibrinogen,platelet aggregation rate were significantly lower than those of the control group(P<0.05).Conclusion:On the basis of conventional treatment,the coronary heart disease patients with PCI are given ticagrelor treatment,and the effect is significant,which can effectively improve the coagulation function of patients,reduce MPAR.%目的：分析替格瑞洛与氯吡格雷在经皮冠状动脉介入治疗(PCI)冠心病患者中的临床效果。方法：收治PCI治疗冠心病患者90例，随机分为研究组和对照组各45例，对照组给予氯吡格雷治疗，研究组给予替格瑞洛治疗，比较两组治疗前后的凝血功能指标变化及血小板聚集率的变化情况。结果：治疗后，研究组活化部分凝血活酶时间、凝血酶原时间明显短于对照组，凝血酶时间明显长于对照组，纤维蛋白原、血小板聚集率明显低于对照组(P＜0.05)。结论：PCI 治疗的冠心病患者在常规治疗的基础上加用替格瑞洛治疗，效果显著，有效改善患者的凝血功能，降低MPAR(血小板聚集率)。